The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJust Group Regulatory News (JUST)

Share Price Information for Just Group (JUST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 103.00
Bid: 103.00
Ask: 103.40
Change: 1.60 (1.58%)
Spread: 0.40 (0.388%)
Open: 103.60
High: 104.00
Low: 101.80
Prev. Close: 101.40
JUST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IFRS 17 FY 2022 and H1 22 restatement

11 Jul 2023 07:00

RNS Number : 5666F
Just Group PLC
11 July 2023
 

 

 

A PDF copy of this announcement is available here >

 

 

http://www.rns-pdf.londonstockexchange.com/rns/5666F_1-2023-7-10.pdf

NEWS RELEASE

www.justgroupplc.co.uk

11 July 2023

JUST GROUP plc

IFRS 17 FY 2022 and H1 22 restatement 

 

Just Group plc ("Just", the "Group") has today made presentation slides available on the Group's website www.justgroupplc.co.uk, and below, provides a restatement of its financial results for the year ended 31 December 2022 and the six months ended 30 June 2022 under IFRS 17. IFRS 17 is a new accounting standard for insurers, which was implemented on 1 January 2023.

 

We remain committed to our ambition to target 15% growth in underlying operating profit.

Under IFRS 17, we will continue our commitment to deliver 15% growth in underlying operating profit per annum over the medium term. In 2022, we delivered 19% growth in underlying operating profit under IFRS 4. Our IFRS 17 measure for underlying operating profit is explained further below.

Our target to deliver a greater than 10% return on equity will also continue under IFRS 171.

 

No change in strategy, growth ambition, capital, cash or dividend policy

IFRS 17 is an accounting change and does not affect the underlying economics of our business or our strategy

·

Our commitment and ability to invest in future growth is unchanged

·

The capital strength of the Group is unchanged

·

Our new and existing business cashflows are unchanged

·

The Group's dividend policy is unchanged

·

The Group's debt leverage is unchanged

 

Effect of transition to IFRS 17

Under IFRS 17 total economic profits do not change, but how these are accounted for does. IFRS 17 introduces two new balance sheet concepts - the Contractual Service Margin ("CSM") and Risk Adjustment ("RA"), which are stocks of discounted future value that are released into reported profit over time. These stocks of future value are added to by future new business, which in turn also releases over time.

· Underlying operating profit is broadly unchanged for FY22: £257m under IFRS 17 versus £249m under IFRS 4. To provide a meaningful measure of business performance, we add back the net underlying CSM increase during the year to derive underlying operating profit under IFRS 17.

 

· The Group's shareholder value is broadly unchanged with TNAV per share at 31 December 2022 under IFRS 17 of 190p per share versus 172p under IFRS 4

o IFRS 17 Adjusted shareholders equity on 31 December 2022 of £2.0bn (31 December 2021: £2.1bn) is comprised £783m of IFRS 17 Equity attributable to shareholders (31 December 2021: £1,175m) and £1,212m of CSM net of tax (31 December 2021: £966m).

o The CSM growth was driven by the addition of new business, whilst the IFRS 17 equity fell largely due to economic losses resulting from the interest rate hedging programme. During 2022, we actively reduced the level of interest rate hedging as the capital position strengthened, with the sensitivity remaining close to zero in 2023.

o The increase in TNAV per share includes 6p (£80m pre-tax) which arises from the reversal of a negative investment timing impact on the large volume of business written in Q4 22 that was recognised under IFRS 4, but is not recognised under IFRS 17

 

· Return on Equity is broadly unchanged: 10.3% under IFRS 17 vs 10.7% under IFRS 4

Under IFRS 17, the Return on Equity was 10.3%. The slightly higher IFRS 17 Underlying operating profit has been offset by a slightly higher IFRS 17 Adjusted shareholders equity.

Our intention is to continue growing the Return on Equity from this level.

 

 

IFRS 17 - Results for the Year Ended 31 December 2022

All figures presented are unaudited.

IFRS 17 based Key Performance Indicators

Year ended

Six months

31-Dec

30-Jun

2022

2022

£m

£m

New business profit1

266

76

Underlying operating profit1

257

68

IFRS (loss)/profit before tax

(494)

(237)

Return on equity1,2

10.3%

5.4%

TNAV per share1

190p

187p

 

Underlying Operating Profit

Year ended

Six months

 

31-Dec

30-Jun

2022

2022

£m

£m

New business profits

266

76

CSM amortisation3

(61)

(27)

Net underlying CSM increase

205

50

In-force operating profit4

156

72

Other Group companies' operating results

(16)

(7)

Development expenditure5

(15)

(9)

Finance costs

(73)

(37)

Underlying operating profit1

257

68

 

Operating Profit METRICS

Year ended

Six months

 

31-Dec

30-Jun

2022

2022

 

 

Retirement Income sales1 (£m)

3,131

879

New business margin1 (%)

8.5%

8.6%

Underlying Operating EPS1 (p per share)

20.2p

5.3p

 

Reconciliation of Underlying Operating Profit to Statutory IFRS

Year ended

Six months

 

31-Dec

30-Jun

2022

2022

£m

£m

Underlying operating profit 1

257

68

Operating experience and assumption changes6

104

(4)

Adjusted operating profit/(loss) before tax 1

361

64

Investment and economic movement

(537)

(255)

Strategic expenditure5

(7)

(3)

Interest adjustment to reflect IFRS accounting for Tier 1 notes as equity

16

9

Profit/(loss) before tax prior to deferral of profit to CSM

(167)

(185)

Deferral of profit in CSM7

(327)

(52)

Profit/(loss) before tax

(494)

(237)

 

See notes at the end of the release

 

Reconciliation from IFRS4 to IFRS17

Underlying operating profit

Year ended

Six months

31-Dec

30-Jun

2022

2022

£m

£m

As presented in 2022 Annual Report and Accounts under IFRS 4

249

74

Changes in allowances for credit defaults

25

5

Changes attributable to replacement of IFRS 4 prudent reserves with IFRS 17 risk adjustment

(9)

(4)

Reclassification of expenses

(6)

(3)

Other differences

(3)

(4)

Restated underlying operating profit1

257

68

 

Tangible Net Assets and Return on Equity

31-Dec-22

30-Jun-22

31-Dec-21

£m

£m

£m

Total equity attributable to ordinary shareholders of Just Group plc

783

979

1,175

Less intangible assets

(47)

(46)

(45)

Tax on intangibles

3

3

3

Add back contractual service margin

1,611

1,336

1,284

Adjust for tax on contractual service margin

(399)

(331)

(318)

IFRS 17 Tangible Net Assets1

1,951

1,941

2,099

IFRS 17 Tangible Net Assets per share1

190p

187p

203p

Return on equity % (underlying) 1

10.3%

5.4%

 

 

Tangible Net Asset Value per share (pence) is the Tangible Net Asset Value of the Group divided by the number of shares in issue, adjusted for the treasury shares held by the Group

 

 

Condensed Consolidated Statement of Financial Position

31-Dec-22

30-Jun-22

31-Dec-21

£m

£m

£m

Assets

 

Financial investments

23,477

22,789

24,682

Reinsurance contract assets

776

599

716

of which CSM

107

51

54

Other assets

1,285

1,062

1,003

Total assets

25,538

24,450

26,401

Share capital and share premium

199

199

199

Other reserves

585

780

977

Total equity attributable to ordinary shareholders of Just Group plc

783

979

1,175

Tier 1 notes

322

322

322

Non-controlling interest

(2)

(2)

(2)

Total equity

1,103

1,299

1,496

Liabilities

Insurance contract liabilities

19,647

19,559

23,086

of which CSM

1,943

1,523

1,489

Reinsurance contract liabilities

121

146

165

of which CSM

(225)

(136)

(151)

Other financial liabilities

4,378

3,302

1,529

Other liabilities

289

144

125

Total liabilities

24,435

23,151

24,905

Total equity and liabilities

25,538

24,450

26,401

Total Contractual Service Margin included above

1,611

1,336

1,284

Contractual Service Margin net of deferred tax

1,212

1,006

966

 

Note 1: Alternative performance measure (APM). In addition to statutory IFRS performance measures, the Group has presented a number of non-statutory alternative performance measures. The Board believes that the APMs used give a more representative view of the underlying performance of the Group. There have been changes to APMs since the 2022 Annual Report and Accounts. The tables and footnotes above explain the basis of their calculation. Net underlying CSM increase is added back to calculate underlying operating profit as the Board considers the value of new business is significant in assessing business performance.

Note 2: Return on equity is IFRS 17 underlying operating profit after attributed tax divided by the average IFRS 17 adjusted shareholders equity less goodwill.

Note 3: CSM amortisation represents the net release from the CSM reserve into profit as services are provided. The figures are net of accretion (unwind of discount), and the release is computed based on the closing CSM reserve balance for the period.

Note 4: In-force operating profit represents profits from the in force portfolio before investment and insurance experience variances, and assumption changes. It mainly represents release of risk adjustment for non-financial risk and of allowances for credit default in the period, investment returns earned on shareholder assets, together with the value of the CSM amortisation.

Note 5: Following a review of expense allocation to bring consistency with Solvency II KPIs, non recurring costs have been reallocated to development expenditure and strategic expenditure. Development expenditure relates to the development of existing products, markets, technology, and transformation projects.  Strategic expenditure relates to major strategic investment, new products and business lines, and major regulatory projects.

Note 6: Operating experience and assumption changes represent changes to cash flows in the current and future periods valued based on end of period economic assumptions.

Note 7: Deferral of profit in CSM represents the total movement on CSM reserve in the year. The figure represents CSM recognised on new business, accretion of CSM (unwind of discount), transfers to CSM related to changes to future cash flows at locked-in economic assumptions, less CSM release in respect of services provided.

Note 8: All the figures are unaudited.

 

Further Information

Please contact the Investor Relations team, details below.

 

FINANCIAL CALENDAR AND TIMELINES

DATE

BASIS

Interim results for the six months ended 30 June 2023

15 August 2023

First financial reporting under IFRS 17

 

 

Enquiries

 

Investors / Analysts

 

Alistair Smith, Investor Relations

Telephone: +44 (0) 1737 232 792

alistair.smith@wearejust.co.uk

 

Paul Kelly, Investor Relations

Telephone: +44 (0) 20 7444 8127

paul.kelly@wearejust.co.uk

 

 

 

 

Media

 

Stephen Lowe, Group Communications Director

Telephone: +44 (0) 1737 827 301

press.office@wearejust.co.uk

 

Temple Bar Advisory

Alex Child-Villiers

William Barker

Telephone: +44 (0) 20 7183 1190

 

A copy of this announcement will be available on the Group's website www.justgroupplc.co.uk

 

JUST GROUP PLC

GROUP COMMUNICATIONS

Enterprise House

Bancroft Road

Reigate

Surrey RH2 7RP

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FR NKKBDCBKDKOD
Date   Source Headline
25th Apr 202410:04 amRNSDirector/PDMR Shareholding
12th Apr 202410:00 amRNSDirector/PDMR Shareholding
2nd Apr 20245:20 pmRNSDirector/PDMR Shareholding
26th Mar 20244:09 pmRNSHolding(s) in Company
26th Mar 20244:08 pmRNSHolding(s) in Company
26th Mar 20243:41 pmRNSAnnual Report and Accounts and Notice of AGM
8th Mar 20247:00 amRNSResults for the year ended 31 December 2023
7th Mar 20244:00 pmRNSHolding(s) in Company
6th Mar 20244:00 pmRNSHolding(s) in Company
4th Mar 20244:30 pmRNSHolding(s) in Company
5th Feb 20245:00 pmRNSHolding(s) in Company
31st Jan 20243:30 pmRNSHolding(s) in Company
26th Jan 20241:49 pmRNSHolding(s) in Company
25th Jan 20245:30 pmRNSDirector Declaration
22nd Jan 20244:43 pmRNSHolding(s) in Company
18th Jan 20244:55 pmRNSHolding(s) in Company
18th Jan 20247:00 amRNSBUSINESS UPDATE FOR YEAR ENDED 31 DECEMBER 2023
17th Jan 20244:12 pmRNSHolding(s) in Company
12th Jan 20243:01 pmRNSHolding(s) in Company
10th Jan 20241:31 pmRNSHolding(s) in Company
4th Jan 20244:25 pmRNSHolding(s) in Company
1st Dec 202311:32 amRNSBlock listing Interim Review
28th Nov 20233:00 pmRNSDirector/PDMR Shareholding
23rd Nov 20233:04 pmRNSDirectorate Change
13th Oct 202310:41 amRNSDirectorate Change
28th Sep 202310:13 amRNSDirector/PDMR Shareholding
16th Aug 20232:04 pmRNSHolding(s) in Company
15th Aug 20237:00 amRNSINTERIM RESULTS FOR THE SIX MONTHS ENDED 30/6/2023
20th Jul 20233:00 pmRNSHolding(s) in Company
18th Jul 20237:00 amRNSBusiness update for the six months to 30 June 2023
12th Jul 202310:34 amRNSDirectorate Change
11th Jul 20237:00 amRNSIFRS 17 FY 2022 and H1 22 restatement
6th Jul 20237:00 amRNSDirectorate Change
28th Jun 20239:36 amRNSHolding(s) in Company
1st Jun 202310:00 amRNSBlock listing Interim Review
25th May 20234:00 pmRNSHolding(s) in Company
9th May 20231:02 pmRNSResult of AGM
3rd May 20239:30 amRNSDirectorate Change
13th Apr 202312:05 pmRNSDirector/PDMR Shareholding
3rd Apr 202312:05 pmRNSDirector/PDMR Shareholding
24th Mar 20234:50 pmRNSAnnual Financial Report and Notice of AGM
24th Mar 202311:06 amRNSDirector/PDMR Shareholding
7th Mar 20237:00 amRNSResults for the year ended 31 December 2022
1st Mar 20231:08 pmRNSDirectorate Change
6th Feb 20237:00 amRNSIFRS 17 UPDATE
26th Jan 20237:00 amRNSBUSINESS UPDATE FOR THE YEAR ENDED 31 DEC 2022
5th Jan 202310:19 amRNSDirectorate Change
9th Dec 202212:15 pmRNSDirector/PDMR Shareholding
1st Dec 20221:32 pmRNSBlock listing Interim Review
11th Nov 202210:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.